Nanotechnology Patents

Nanomaterials occupy a complex patent eligibility space because the boundary between naturally occurring phenomena and human-engineered innovations requires careful analysis: CARBON NANOTUBES — ORIGIN AND PATENT LANDSCAPE: Sumio Iijima at NEC (1991) published the definitive paper on multi-walled carbon nanotubes (MWCNTs), though earlier observations existed; NEC held key early patents; the Iijima paper is foundational prior art for nanotube properties; COMMERCIAL CNT PATENT HOLDERS: Nano-C (Harvard spinoff): purification and functionalization; Carbon Nanotube Corp; Stanford: CNT transistors and electronics applications; RICHARD SMALLEY (RICE UNIVERSITY): buckminsterfullerene (C60; 'buckyball') Nobel Prize 1996; foundational patents on fullerene synthesis and applications; PATENT ELIGIBILITY FOR CNTs: the specific structure of single-walled CNTs (specific chirality; specific diameter range) created in a specific way that does not occur in nature = patentable; the process of manufacturing CNTs = clearly patentable; applications (CNT composites; CNT field-effect transistors) = patentable; GRAPHENE — NOBEL AND PATENT RACE: Andre Geim and Konstantin Novoselov (University of Manchester) isolated graphene via scotch tape exfoliation in 2004; Nobel Prize 2010; Manchester did not file patents on the basic discovery (a controversial decision); LARGEST GRAPHENE PATENT FILERS: Samsung: consistently the largest graphene patent filer globally (thousands of applications); focus on flexible displays; electronics; energy storage; IBM: graphene transistors for high-frequency (GHz-THz) radio frequency electronics; graphene does not have a bandgap, making it unsuitable for digital logic without modification; Graphenea (Spanish): graphene production and supply; GRAPHENE PATENT ELIGIBILITY: the graphene allotrope of carbon is a naturally occurring material; graphite contains graphene layers; strictly isolated graphene = ambiguous Myriad analysis; HOWEVER: specific graphene devices (graphene FET; graphene composite materials; graphene oxide derivatives with specific properties); specific graphene production methods; specific graphene films with non-natural characteristics are clearly patentable; QUANTUM DOTS — BROAD APPLICATIONS: semiconductor quantum dots (CdSe; InP; ZnS) for: display backlighting (QLED TVs: Samsung Nanosys licensing arrangement; QD Vision acquired by Samsung); medical imaging (in vivo fluorescent labeling); quantum computing (spin qubits); QUANTUM DOT PATENT LEADERS: Nanosys (spun out of Harvard; key QLED supply patents); Samsung: QLED display stack patents; QD Vision (now part of Samsung); MIT/Harvard foundational quantum dot synthesis and application patents.

Lipid nanoparticle (LNP) technology became one of the most commercially significant patent areas in pharmaceutical history when it enabled the first FDA-approved mRNA COVID-19 vaccines: WHAT LIPID NANOPARTICLES ARE: LNPs are nanoscale vesicles (~50-200 nm diameter) made of lipid components that encapsulate and protect therapeutic nucleic acids (mRNA; siRNA; plasmid DNA) and deliver them into cells; the lipid composition typically includes: IONIZABLE LIPID: key innovation; positively charged at low pH (for nucleic acid binding) but neutral at physiological pH (reduces toxicity); PHOSPHOLIPID: structural; stabilizes the particle; CHOLESTEROL: helps with endosomal escape and stability; PEG-LIPID: reduces immune recognition; increases circulation time; HISTORICAL DEVELOPMENT: Pieter Cullis and Ian Cullis lab (University of British Columbia): pioneered LNP technology for gene therapy in the 1990s; foundational UBC patents licensed to multiple companies; ARBUTUS BIOPHARMA (formerly Tekmira): major LNP patent portfolio holder; key patents on ionizable lipid LNP formulations; US8,058,069 covers specific LNP compositions; ALNYLAM PHARMACEUTICALS: developed LNP delivery for siRNA therapeutics; Onpattro (patisiran; 2018): first FDA-approved LNP-delivered siRNA; validated the commercial value of LNP patents; key Alnylam LNP patents: specific ionizable lipid structures; LNP manufacturing processes; LNP-siRNA formulations; COVID-19 VACCINE PATENT CONTROVERSY: both Moderna mRNA-1273 and Pfizer-BioNTech BNT162b2 use LNP technology: Moderna had licensed certain Arbutus LNP patents before COVID but disputed the scope of that license; Arbutus sued Moderna post-COVID for patent infringement; claimed Moderna's COVID vaccine used unlicensed Arbutus LNP IP; Moderna argued the licensed patents covered COVID vaccine LNPs; Alnylam: asserted that some of Moderna's LNP patents derived from Alnylam technology; THE CURRENT LANDSCAPE: multiple overlapping LNP patent portfolios make mRNA therapeutics a complex licensing environment; BEYOND COVID — FUTURE mRNA THERAPEUTIC APPLICATIONS: mRNA cancer vaccines (Moderna; BioNTech; CureVac): individualized neoantigen vaccines; LNP delivery is essential; mRNA therapeutics for genetic diseases; in vivo gene editing (CRISPR delivered via LNP): the Intellia/CRISPR Therapeutics approach; each new application requires analysis of which LNP patents apply.

While LNPs have dominated recent attention due to COVID vaccines, the broader nanoparticle drug delivery landscape includes polymeric nanoparticles, inorganic nanoparticles, and protein-based systems with distinct patent landscapes: POLYMERIC NANOPARTICLES: PLGA NANOPARTICLES: poly(lactic-co-glycolic acid) nanoparticles are the most clinically used biodegradable polymer nanoparticles; FDA-approved for drug delivery (Lupron Depot; Risperdal Consta); PLGA polymer is not patentable (widely used and off-patent) but specific PLGA nanoparticle formulations can be patented; MIT ROBERT LANGER LAB: extremely prolific polymer nanoparticle IP; BIND Therapeutics (MIT spinoff): targeted PLGA nanoparticles with antibody targeting ligands; CALIFORNIA INSTITUTE OF TECHNOLOGY (CALTECH): Mark Davis lab: cyclodextrin-based polymer nanoparticles for siRNA; Calando Pharmaceuticals clinical application; DENDRIMER NANOPARTICLES: tree-like polymer structures with controlled branching; Starpharma (Australian): VivaGel (polylysine dendrimers for STI prevention); DOW CHEMICAL: PAMAM dendrimers (polyamidoamine); ALBUMIN-BOUND NANOPARTICLES: ABRAXANE (PACLITAXEL + ALBUMIN): Abraxis/Celgene/AstraZeneca: nab-paclitaxel = paclitaxel bound to albumin nanoparticles (~130 nm); key patents: the nab-technology = nanoparticle albumin-bound technology (US6,537,579; US7,820,788); dramatically different pharmacokinetics from Taxol (paclitaxel in Cremophor EL); FDA-approved for breast cancer; NSCLC; pancreatic cancer; the Abraxane story shows how reformulating an existing drug as a nanoparticle can create entirely new, highly valuable patent estates; INORGANIC NANOPARTICLES: GOLD NANOPARTICLES: Nanospectra Biosciences (James West/Rice University): AuroShell — gold nanoshells with silica core for photothermal ablation of tumors; FDA clearance for prostate cancer treatment; patents on specific gold-silica nanoshell dimensions and optical properties; diagnostic applications: lateral flow assay nanoparticles (widespread use; heavy competition); IRON OXIDE NANOPARTICLES (SPIONs): superparamagnetic iron oxide for MRI contrast enhancement; Ferumoxytol (Feraheme; AMAG Pharmaceuticals): iron deficiency treatment and off-label MRI contrast; basic SPIONs are widely practiced but specific coatings and targeting ligands are patentable; MESOPOROUS SILICA NANOPARTICLES (MSN): very high surface area; good for loading large drug amounts; UCLA (Jeffrey Zink lab); MIT; loading + gating mechanisms are patentable.

Nanotechnology IP strategy requires addressing fundamental questions about patent eligibility for nanomaterials while building strong protection around manufacturing innovations and specific applications: PATENT ELIGIBILITY FRAMEWORK FOR NANOMATERIALS: APPLYING MYRIAD TO NANO: Myriad Genetics (S.Ct. 2013): naturally occurring products = not patentable; isolated naturally occurring products = not patentable; products with markedly different characteristics from nature = patentable; NANO-SPECIFIC APPLICATION: if a nanomaterial form is found in nature (combustion products; meteorites; biological systems), isolated versions may face eligibility challenges; the key question: does your nanomaterial have markedly different properties from anything found in nature?; STRONG PATENT POSITIONS IN NANO: specific nanoparticle compositions with precisely controlled dimensions (specific size; specific size distribution); specific surface modifications that create non-natural chemical environments; specific nanocomposite materials combining nanoscale and bulk materials in non-natural ways; MANUFACTURING PROCESS PATENTS: the specific synthesis method for creating nanoparticles with desired properties (sol-gel; hydrothermal; chemical vapor deposition variant; electrospinning); scale-up manufacturing processes (continuous manufacturing vs. batch); quality control methods (specific characterization and release testing protocols for nanoparticles); manufacturing process patents are often more durable than composition patents because they are harder to design around; APPLICATION-SPECIFIC PATENTS: drug delivery: specific nanoparticle formulation for specific drug + specific targeting + specific release profile; materials: specific nanocomposite structure + fabrication + measured property improvement; electronics: specific device architecture incorporating nanomaterials + fabrication method; diagnostics: specific nanoparticle label + detection method + clinical application; TRADE SECRET COMPLEMENT: certain nanotechnology manufacturing know-how is best protected as trade secrets: specific supplier relationships for raw nanomaterials; specific process parameters for reproducible nanoparticle synthesis; characterization methods for batch quality; FREEDOM-TO-OPERATE IN NANO: nanoparticle drug delivery requires FTO analysis against LNP patents (Alnylam; Arbutus; Moderna; UBC); CNT patents (NEC; Nano-C); graphene patents (Samsung; IBM); quantum dot patents (Nanosys); NANOSAFETY AND REGULATORY CONSIDERATIONS: EPA Toxic Substances Control Act (TSCA) nanomaterial reporting; FDA guidance on nanomaterial drug products (2014 guidance; 2018 Q&A); REACH regulations for nanomaterials in EU; regulatory compliance creates additional IP considerations around novel testing methods.